Plasma Fractionation Market to Touch USD 72.86 Bn by 2034

Plasma Fractionation Market Companies, Shares and Trends

The global plasma fractionation market size was estimated at US$ 32.75 billion in 2023 and is projected to grow to US$ 72.86 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. The rising therapeutic demand for plasma is boosting the plasma fractionation market.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

Plasma fractionation is a complex process to separate blood plasma into individual components, predominantly protein which includes clotting factors, albumin, immunoglobulins and fibrinogens, other components are enzymes and antibodies with phenomenal therapeutical values. Plasma fractionation is widely used in pharmaceutical research to treat chronic diseases. The worldwide rising demand for plasma derivatives due to increased immune disease, coagulation disorders and genetic defects is fuelling the market growth.

Plasma Fractionation Market Trends

• In September 2024, Epsilogen, a global leading biotechnology company in London, expanded its financing round by raising $16.4 million to process the development of its immunoglobulin E (IgE) antibodies for cancer treatment. The investment was sourced by the British Patient Capital, the Novartis Venture Fund, Epidarex Capital, the 3B Future Health Fund and ALSA Ventures.
• In June 2024, Biotest, a global company that supplies plasma protein products and biotherapeutic drugs, controlled by Grifols, a globally leading healthcare company, received FDA approval for marketing Yimmugo – a treatment of primary humoral immunodeficiency (PI) in patients 2 years of age or older.
• In July 2024, the Independent Health and Aged Care Pricing Authority announced Activity Based Funding (ABF) for home-delivered subcutaneous immunoglobulin (SCIg) infusion therapy. This therapy is a non-admitted patient service performed by patients at their homes without a healthcare provider.

Chromatography is the Future of Plasma Fractionation Market

The chromatography-based method for plasma separation rapidly gaining popularity as offers gradual improvement, improves purity and enables the production of new classes of therapeutics. Plasma contains over 120 varieties of protein. When these proteins are extracted pure and concentrated, they can create life-saving therapeutics which are crucial for the treatment of several diseases such as immune deficiencies and bleeding disorders.

Even today, modern plasma fractionation technology relies on the original, ethanol-based protocol which is mostly used to isolate albumin. To produce novel plasma products which can be used to treat protein deficiencies, it is essential to implement chromatographic techniques. This precise technique has the ability to capture even trace protein. With the help of ion-exchange chromatography (IEC), proteins at their original pH and ionic strength, even fragile proteins (such as coagulation factors, anticoagulants, and protease inhibitors) are preserved and isolated.

Risk of Sepsis: Market’s Major Restraint

A study published in the journal Science Translational Medicine mentions a pattern developing with certain blood plasma protein levels that can lead to the development of sepsis in patients. A team of medical researchers analysed the plasma profiles of hundreds of ICU patients who had developed sepsis. When the body shows dysregulated response to infection, it the known as sepsis condition. It is considered a life-threatening condition as it leads to multiple organ failure. Every year in the United Kingdom approximately 50,000 deaths are noted due to sepsis.

The researchers drew out plasma samples from 16,000 patients and measured protein levels for plasma proteome using tandem mass spectrometry and liquid chromatography on 2,600 samples. The results provide a general profile which is used to identify patients at risk.

Regional Insights

Investments in R&D with Fundings: North America to Sustain as a Leader

North America dominated the global plasma fractionation market in 2023. The unites states is the largest supplier of Plasma Fractionation in the world. As US has a policy of paid donors while other countries obtain plasma from volunteers and unpaid donors. Therefore, the rate of plasma collection is less in other countries. Canadian Blood Service uses raw plasma to produce a category of drugs such as plasma protein and related products. Additionally, the three largest plasma product companies in the U.S. – CSL Plasma, Grifols and BioLife, collect over 75% of total plasma for fractionation in the States. That are about 54% more plasma donation centres in the US than there were four years back. With the rising demand for plasma on every basis of 6,500 units, there needs to be a consistent donation rate.

Europe to Witness a Growing Industry in Upcoming Period

Europe is anticipated to register the fastest growth in the haptic devices market during the forecast period of 2024 to 2034. The growth in this region depends upon the European Union's attainment of open strategic autonomy and improved competitiveness. European Union institutes, governments and businesses are working towards a better understanding of potential vulnerabilities and opportunities to modify policies to ensure a resilient supply of plasma and plasma-derived medicinal products. This action will provide a better solution for the EU and national level to achieve recognition.

Segmental Insights

By type, Immune Globulin dominated the plasma fractionation market in 2023. The growth of this segment is noticed by plasma-derived immunoglobulins are provided with a new narrative in the healthcare industry for a wide range of autoimmune inflammatory diseases. Immune globulin is needed for a patient who cannot make enough antibodies. This provides externally sourced antibodies for recovery. 

The Coagulation Factor segment is expected to grow significantly in the plasma fractionation market during the forecast period of 2024 to 2034. The expansion of this segment is observed due to its ability to stop bleeding when injured. It includes a system of proteins that controls the conversion of soluble plasma fibrinogen to fibrin, an insoluble polymer that forms a gel network to stop bleeding.

By application, the hospital segment stood dominant in the plasma fractionation market in 2023. The dominance is observed due to the wide utilization of plasma at hospitals for emergency cases to boost blood volume in trauma patients, prevent shock and help with blood clotting. Healthcare providers supply various plasma-derived medicinal products to hospitals and other healthcare facilities for the treatment of patients with immune deficiency disorders, immunodeficiency virus, hepatitis virus and many more.

The retail pharmacy segment is anticipated to grow with the highest CAGR in the plasma fractionation market during the studied years. Pharmaceutical companies extract components from raw human plasma using centrifugation, depth filtration and chromatographic methods. The manufacturing process is carried out to produce effective and safe drugs.

Top Companies in Plasma Fractionation Market

• Syntegon
• CSL Behring
• Grifols Therapeutics
• Mitsubishi Tanabe
• Octapharma AG
• Hualan Bio
• Kedrion S.p.A
• Takeda Pharmaceutical Company Ltd.
• LFB Group
• Intas Pharmaceuticals Ltd.
• Biotest AG
• Bio Product Laboratory Ltd.

Latest Announcements by Industry Leaders

• In July 2024, Spanish drugmaker Grifols, known for its plasma-derived medicines, announced Rahul Srinivasan as its new Chief Financial officer. He appreciates this new work post and thanks Nachi Abia the CEO of Grifols he states,” the Board of the venerable institution that has made a huge difference to people’s lives with its portfolio of life-changing medicines across a wide arrange of therapeutic areas.”
• In June 2024, Roland Wandeler, President of Grifols Biopharma Business Unit comments on Biotest’s Yimmungo, “the Yimmungo will provide a strong portfolio of intravenous and subcutaneous immunoglobulins provides another innovative treatment option for patients with primary immunodeficiencies who reply of these essential medicines in their daily lives.”

Recent Developments

• In August 2024, Nanoform Finland, the medicine performance-enhancing company is developing pre-clinical plasma-derived therapies with Takeda Pharmaceutical Company. The aim is to develop plasma-derived therapy formulations for the treatment of rare conditions.
• In September 2024, GEFD – a joint venture between Grifols and Egypt’s National Service Project Organisation (NSPO) launched a project as a national initiative to achieve self-sufficiency in plasma-derived medicine, which is a vital treatment extracted from blood plasma for various medical conditions. The project includes a plasma laboratory, plasma warehouse, 20 donation centres and a state-of-art manufacturing facility.

Segments Covered in this Report

By Type

• Albumin
• Immune Globulin
• Coagulation Factor
• Others

By Application

• Hospital
• Retail Pharmacy
• Other

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait